Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03447990 · ClinicalTrials.gov registry record · Phase 1
v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT03447990 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 52 participants.
The verdict
NCT03447990, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
Interventions
- DRUG Placebo
- DRUG MYK-491
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-02-06 |
| Est. Completion | 2019-10-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03447990
The ClinicalTrials.gov registry entry for NCT03447990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03447990 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03447990 about?
NCT03447990 is a clinical study titled "v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491". The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
What is the current status of trial NCT03447990?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2018-02-06. Estimated completion is 2019-10-24.
What interventions are being tested in trial NCT03447990?
The interventions under investigation include: Placebo (DRUG), MYK-491 (DRUG).
Who is sponsoring clinical trial NCT03447990?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.